CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Pravastatin +1 moredrug
Likely dose
Pravastatin 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02841774
NCT02841774Phase 2Completed
CompareCT.gov

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With Human Immunodeficiency Virus (HILLCLIMBER)

Matthew Feinstein·interventional·Posted Jul 22, 2016·Updated Oct 18, 2022

In Brief

A Phase 2 clinical trial evaluating Pravastatin and Rosuvastatin for HIV Infection and Coronary Heart Disease. Completed, enrolled 10 participants across 1 site.

Detailed Summary

HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily) in HIV-infected persons taking antiretroviral therapy (ART) who have coronary heart disease (CHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection, Coronary Heart Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 22, 2016
Enrollment StartNov 1, 2016
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 9.9 years ago

Interventions

Pravastatindrug

40mg daily (Weeks 2 - 14)

Rosuvastatindrug

20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily